Author:
Shao Jie,Xu Qiuping,Su Shu,Meng Fanyan,Zou Zhengyun,Chen Fangjun,Du Juan,Qian Xiaoping,Liu Baorui
Funder
National Natural Science Foundation of China
Natural Science Foundation of Jiangsu Province
Reference57 articles.
1. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial;Weber;Lancet Oncol.,2015
2. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma;Ansell;N. Engl. J. Med.,2015
3. PD-1 blockade in tumors with mismatch-repair deficiency;Le;N. Engl. J. Med.,2015
4. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy;Taube;Clin. Cancer Res.,2014
5. Pembrolizumab for the treatment of non-small cell lung cancer;Lim;Expert Opin. Biol. Ther.,2016
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献